Hong Kong Stock Movement
BIOCYTOGEN-B surged 20.35%. Based on recent news,
<ol>
<li>
On December 24, BIOCYTOGEN-B was included in the Hong Kong Stock Connect, effective today. Following this announcement, the stock price rose significantly, and trading volume increased notably.
</li>
<li>
On December 24, the Shanghai and Shenzhen Stock Exchanges announced that the price stabilization period for BIOCYTOGEN-B in the Hong Kong market had ended and that the corresponding A shares had been listed for more than 10 trading days, meeting the criteria for inclusion in the Hong Kong Stock Connect, further driving up the stock price.
</li>
<li>
On December 24, the Shenzhen Stock Exchange issued an announcement confirming that BIOCYTOGEN-B was included in the list of securities eligible for the Hong Kong Stock Connect, and the stock price continued to rise after the news was released. The adjustment of the Hong Kong Stock Connect drove the stock price up.
</li>
</ol>
Stocks with High Trading Volume in the Industry
Innovent Biologics fell 0.43%. Based on recent key news:
<ol>
<li>
On December 23, Innovent Biologics signed a memorandum of understanding with the Shanghai Municipal Market Supervision Administration to strengthen corporate compliance governance and reduce compliance risks. This collaboration may enhance market confidence in Innovent Biologics, although the stock price may fluctuate in the short term.
</li>
<li>
On December 23, the National Healthcare Security Administration announced an adjustment plan for the innovative drug catalog to support the payment of innovative drugs. As an innovative pharmaceutical company, Innovent Biologics may benefit from policy support, driving long-term growth.
</li>
<li>
On December 23, Innovent Biologics' product pipeline spans multiple fields, with annual revenue approaching 10 billion, demonstrating its significant position in the global pharmaceutical market. Despite short-term stock price fluctuations, the long-term outlook remains optimistic. There is increasing policy support for the innovative drug industry.
</li>
</ol>
Zai Lab rose 4.92%. Based on recent key news:
<ol>
<li>
On December 23, Zai Lab announced that the National Medical Products Administration of China had approved the new drug application for Neflamapimod capsules for the treatment of adult schizophrenia. This approval brings positive market expectations for the company, driving the stock price up. Source: Business Wire
</li>
<li>
On December 22, UBS published a research report stating that despite facing several adverse factors, Zai Lab remains optimistic about its long-term growth potential and reiterated its &#34;Buy&#34; rating. UBS believes that the company's key assets have not yet been reflected in the stock price and expects multiple asset catalysts to drive the company's recovery. Source: UBS
</li>
<li>
On December 24, based on positive data from Phase III studies, the sales of Zai Lab's Mablizumab have been increasing year-on-year, further enhancing market confidence in its product line. Source: Yiou Data The competition in the pharmaceutical industry is intensifying, and policy changes need to be monitored.
</li>
</ol>
Kangfang Biologics rose 0.35%. Based on recent news,
<ol>
<li>
On December 23, the global pharmaceutical market landscape is changing, with large pharmaceutical companies increasingly relying on Biotech innovations, driving changes in collaboration models. This trend enhances the negotiating power of Biotech companies, which are expected to capture a larger share of the commercial value pie, driving up the stock price of Kangfang Biologics
</li>
<li>
On December 23, the domestic market predicts that in the next five years, the commercialization of innovative drugs in China will concentrate on platform companies with a scale of 5 billion to 10 billion. As an innovative drug company, KANGFANG BIO is expected to benefit from this process, enhancing market confidence and driving up stock prices.
</li>
<li>
On December 23, Genscript Biotech signed a commercialization service agreement with Haisen Biotech, further enriching its late-stage pipeline layout. This demonstrates the reuse and output of commercialization capabilities among biotech companies, enhancing market confidence in KANGFANG BIO and other biotech firms, and driving up stock prices. The commercialization capabilities of biotech companies are improving, and market confidence is increasing.
</li>
</ol>
Stocks ranked among the top in industry market capitalization
BeiGene rose by 0.11%. Based on recent key news:
<ol>
<li>
On December 22, BeiGene recorded 120,200 shares traded in pre-market trading, with a price of 185.1 yuan per share, the same as the previous day's closing price, with a transaction amount of 22.25 million yuan. This transaction indicates stable market demand for the stock, leading to a slight increase in stock prices. Source: Economic Information Daily
</li>
<li>
No other significant news recently. Market demand for innovative drugs is increasing
</li>
</ol>

02315

BIOCYTOGEN-B surged 20.35%; Innovent Biologics fell 0.43%, with a transaction volume of HKD 115 million; Zai Lab rose 4.92%, with a transaction volume of HKD 109 million; CanSino Biologics increased 0.35%, with a transaction volume of HKD 53.06 million; BeiGene rose 0.11%, with a market capitalization of HKD 283.8 billion

Hong Kong Stock Movement: BIOCYTOGEN-B added to Hong Kong Stock Connect, stock price surges 20.35%, sparking market discussion